RA, $n=13$), RA CMRpos (subclinical CVD-RA, $n=54$), and RA with clinical CVD (defined as history of cerebrovascular disease or ischaemic heart disease) (RA-CVD $n=25$). qPCR of ISGs was performed using TaqMan Gene Expression Assays on Biomark (Fluidigm) with compatible reagents. Factor analysis of Ct values from 51 genes was used to create scores by calculating median dCt for genes loaded by each factor.

Results: RA cohort median(IQR) age 63 (13.3)yrs, 69% female, disease duration 148.7 (215.3)mths; HC age 43 (16.5)y, 62% female. Three IFN-I factors (IFN Score 1, 2, 3) were present in the dataset and were composed of 19, 21 and 7 genes respectively. The Jonckheere-Tepstra test showed significant increases in expression of Score 2 across the 4 groups ($p=0.002$), consistent with a continuum, and multiplicity-corrected post-hoc analysis identified differences between HC and subclinical CVD ($p=0.034$), HC and RA-CVD ($p=0.004$); as well as between no CVD-RA and subclinical CVD-RA ($p=0.034$); and subclinical CVD-RA with RA-CVD ($p=0.029$). Scores 1 and 3 did not show consistent directional trends across all studied groups. In no CVD-RA expression of Score 1 and 2 positively correlated with CRP ($\rho=0.744$, $p=0.002$ and $\rho=0.659$, $p=0.010$ respectively). Score 1 with Low-Density Lipoproteins ($\rho=0.527$, $p=0.044$), Framingham 10y risk ($\rho=0.595$, $p=0.019$) and Score 3 with Pulse Wave Velocity ($\rho=0.584$, $p=0.022$). In subclinical CVD-RA score 3 expression negatively correlated with Left Ventricular mass ($\rho=-0.381$, $p=0.005$), in RA-CVD score 3 expression positively correlated with Glucose ($\rho=0.724$, $p=0.042$), Triglycerides ($\rho=0.821$, $p=0.023$) and Total Cholesterol/High-Density Lipoprotein ratio ($\rho=0.505$, $p=0.039$).

Abstract AB0047 – Figure 1

Conclusions: An IFN-I score (Score 2) emerged as a possible factor characterising progression along a CVD continuum in RA patients, from no CVD to subclinical and clinical CVD; also distinguishing between HC and RA with subclinical and clinical CVD. IFN- α is involved in metabolic disturbances associated with CVD development in RA. These results warrant further evaluation to confirm the findings in a larger cohort.

REFERENCES:

- [1] Kaplan MJ. *Curr. Opin. Rheumatol* 2006;18(3):289–297.
- [2] Somers EC, et al. *PloS one* 2012;7(5):e37000.
- [3] de Winther MPJ. *Arterioscler. Thromb. Vasc. Biol* 2016;36(2):217–218.
- [4] Rodríguez-Carrio J, et al. *Front Immunol* 2018;8.
- [5] Thurlings RM, et al. *Arthritis Rheum* 2010;62:3607–3614.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.4195

AB0048

SERUM CXCL13 LEVELS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND ITS CORRELATION TO DISEASE ACTIVITY AND LUPUS NEPHRITIS

A.M. Abdalla¹, E.A.E. Baraka², M. El-Bhissy³. ¹Rheumatology and Rehabilitation, Aswan University, Aswan; ²Rheumatology and Rehabilitation; ³Clinical Pathology, Benha University, Benha, Egypt

Background: Systemic lupus erythematosus (SLE) is a complex autoimmune disease that is characterised by the production of pathogenic autoantibodies against nuclear structures.¹ B lymphocyte chemoattractant (BLC) or CXC motif ligand 13 (CXCL13) play an important regulatory role of B1 and B2 cell trafficking for activation of autoreactive T helper cells.² CXCL13 can induce trafficking of the CXCR5 +T lymphocyte subset designated as follicular helper T lymphocytes which are specifically involved in production of autoantibodies during the development of lupus.³

Objectives: To detect serum CXCL13 levels in SLE patients and determine its relation to the disease activity and lupus nephritis

Methods: The study included 32 SLE patients and 20 healthy individuals as a control group. Patients' group was further subdivided according to disease activity and renal involvement. Serum samples from all studied individuals were analysed for the concentrations of CXCL13 by ELISA.

Results: There was a high statistically significant increase ($p<0.001$) in the mean of serum CXCL13 on comparing its levels in SLE patients [242 (121.5–855.6) pg/ml] versus control group [73.8 (22.8–120.3) pg/ml], and on comparing its levels in lupus nephritis patients [542.4 (171–855.6) pg/ml] versus other patients without lupus nephritis [212.9 (121.5–580.5) pg/ml]. Moreover, CXCL13 Concentrations were correlated with SLEDAI ($r=0.771$, $p<0.001$) and double-stranded DNA titres ($r=0.374$, $p<0.05$).

Conclusions: Our data suggest that CXCL13 has an important role in pathogenesis of SLE and lupus nephritis. Also, pharmacological regulation of CXCL13 and its receptor CXCR5 may be a useful therapy in lupus nephritis.

Acknowledgements:

- Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. *Journal of Clinical Pathology*. 2003;56(7):481–490.
- Legler, DF, Loetscher, M, Roos, RS, Clark-Lewis, I, Baggiolini, M, Moser, B. B-cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. *J Exp Med* 1998; 187: 655–660
- Schaeferli P, Willmann K, Lang AB, Lipp M, Loetscher P, Moser B. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. *J Exp Med*. 2000;192:1553–62.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.7326

AB0049

EVALUATION OF CASPASE-3, CASPASE-9, CASPASE-14 AND PANNEXIN-1 LEVELS IN BEHÇET'S DISEASE

A. İlhan¹, M.E. Derin², I. Karadağ², H.O. Doğan³, A.C. Urhan², M. Şahin³, A. Şahin². ¹Internal Medicine; ²Rheumatology – Internal Medicine; ³Biochemistry, Cumhuriyet University Medical Faculty, Sivas, Turkey

Background: Behçet's disease (BD) is a rheumatic disease in which various systemic findings such as especially recurrent oral ulcers, and genital ulcers, eye involvement, skin lesions, gastrointestinal involvement, neurological involvement, vascular involvement and arthritis can be seen.¹ The pathogenesis of the disease has not yet been fully understood. Caspases play a central role in apoptotic signal transduction. They are cysteine bound aspartate specific proteases.² There are three main types of caspases, the initiator caspases, the effector caspases and the inflammatory caspases. Pannexin-1 is a high-conduction voltage-gated channel protein that is commonly found in many organs and tissues including sensory systems and both neuronal and non-neuronal cell types.³

Objectives: The aim of this study is to examine the role of initiator, effector and inflammatory caspases in BD and the levels of pannexin duct protein, which is thought to be active in inflammation in BD and to compare clinical findings with healthy individuals.

Methods: Between January 2017 – June 2017, forty-six patients diagnosed with BD admitting to Cumhuriyet University Medical Faculty, Department of Internal Medicine Rheumatology and forty-four healthy volunteers without any rheumatic, systemic and metabolic diseases enrolled in this study. Clinical findings of all patients were recorded. The blood from a peripheral vein using suitable blood tubes was withdrawn to measure serum caspase-3, caspase-9, caspase-14 and pannexin-1 levels. Blood tests were examined by Elisa method in Cumhuriyet University Department of Biochemistry.

Results: The mean serum caspase-3 level was measured as 12.04 (11.25–43.69) pg/ml in BD group and 12.1 (11.19–484.3) pg/ml in healthy control (HC) group. There was no statistically significant difference between two groups ($p=0.143$). The mean serum levels of caspase-9 in the BD group were measured as 22 (5.14–29.33) pg/ml and 22.01 (11.23–850) pg/ml in the HC group. There was no statistically significant difference between the two groups ($p=0.593$). The mean serum caspase-14 level was 6 (5.2–8.21) pg/ml in the BD group and 6.15 (5.7–353) pg/ml in the HC group. There was no statistically significant difference between the two groups ($p=0.053$). The mean serum pannexin-1 levels were 6.36 (4.21–527.2) pg/ml in the BD group and 255.8 (5.38–2000) pg/ml in the HC. Serum pannexin-1 levels were statistically significant higher in the HC group ($p<0.0001$) (figure 1).